Methotrexate intercalated ZnAl-layered double hydroxide

The anticancerous drug methotrexate (MTX) has been intercalated into an ZnAl-layered double hydroxide (LDH) using an anion exchange technique to produce LDH–MTX hybrids having particle sizes in the range of 100–300 nm. X-ray diffraction studies revealed increases in the basal spacings of ZnAl-LDH–MTX hybrid on MTX intercalation. This was corroborated by the transmission electron micrographs, which showed an increase in average interlayer spacing from 8.9 Å in pristine LDH to 21.3 Å in LDH–MTX hybrid. Thermogravimetric analyses showed an increase in the decomposition temperature for the MTX molecule in the LDH–MTX hybrid indicating enhanced thermal stability of the drug molecule in the LDH nanovehicle. The cumulative release profile of MTX from ZnAl-LDH–MTX hybrids in phosphate buffer saline (PBS) at pH 7.4 was successfully sustained for 48 h following Rigter-Peppas model release kinetics via diffusion.

ZnAl-layered double hydroxide intercalated with methotrexate (∼34% loading) promises the possibility of use of ZnAl-LDH material as drug carrier and in controlled delivery.Figure optionsDownload as PowerPoint slideHighlights
► ZnAl-layered double hydroxide methotrexate nanohybrid has been synthesized.
► XRD and TEM studies on nanohybrid revealed successful intercalation of methotrexate.
► TG and CHN analyses showed ∼34 wt% of methotrexate loading into the nanohybrid.
► Possibility of use of ZnAl-LDH material as drug carrier and in delivery.